GIGA-CARBON-NEUTRALITY
12.5.2023 06:16:28 CEST | Business Wire | Press release
GIGA Carbon Neutrality Inc. (“GCN”) today announced the signing of a Strategic Partnership Agreement with London-based Carbon Trade eXchange (“CTX”) and its Australian technology parent company Global Environmental Markets (“GEM”) to globally expand CTX technology and trading.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230511005848/en/
CTX has launched a White Label version of its carbon market technology. The partnership agreement will enable GCN to negotiate deals with carbon trading platforms and regular stock exchanges worldwide to provide buyers spot market access to carbon credits, RECs (Renewable Energy Certificates), and offsets. Thus, an AI and blockchain-technology-powered global carbon marketplace will be created featuring carbon futures contracts based on trusted high-quality carbon credits from hundreds of projects in multiple carbon registries. These include the UNFCCC CDM Registry, Verra VCS, and Gold Standard.
GCN undertakes to support the expansion of the licensing of GEM technology infrastructure for National Carbon Meta-Registries for nations to activate their commitments under the Paris Agreement and the creation of ITMOs or voluntary carbon credits like the recently launched Global Carbon Registry (GCR) and credit standard and the recently released Core Carbon Principles by the Integrity Council for voluntary carbon markets.
CTX, GEM, and GCN will work together to expand origination of voluntary credits globally and execute larger-scale trading of the credits, bringing together the GCN business and financial network with the 15 years of experience embedded in CTX and GEM’s “Technology Infrastructure for the Future of our Planet”.
The CEO of CTX, Wayne Sharpe, stated: “The current carbon markets must scale by a factor of 10 to 100X to reduce CO2 emissions globally and meet the Paris Agreement targets. Current registry infrastructure is insufficient.
Stock Exchanges globally are struggling to handle the unique carbon trading requirements in the voluntary markets – which deliver the much-needed Climate Finance via Carbon Credits. CTX will supply and support the required technology – then the buyers decide ”
The CEO of GCN, Richard Martin, added that “this Strategic Partnership Agreement is a big opportunity for GCN to use its extensive network of partners, affiliates, and investors to fast track our global expansion plans with a proven set of carbon technology infrastructure”.
About Carbon Trade eXchange (CTX): CTX is the world's first and leading Voluntary Carbon Exchange trading multiple credit standards and project types with transparent wholesale pricing. Trading out of HQ in London since 2008, CTX services over 500 members in more than 50 countries worldwide with T+0 trades online 24/7/365.
About Global Environmental Markets (GEM): GEM designs and develops environmental FinTech solutions including trading platforms, exchanges, registries, and interfaces. Headquartered in Australia GEM owns the CTX technology IP plus a suite of B2B / B2C solutions.
About GIGA Carbon Neutrality Inc. (GCN): GCN is a service and product integrator in the global intelligent commercial transportation and equipment market to efficiently realize customers’ carbon neutrality goals. GCN and its partners offer vehicle equipment manufacturing, comprehensive technologies, operation platforms, energy data and carbon credit services. For more information, please visit the website: https://gigacarbonneutrality.com/
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230511005848/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
From Network Automation to Agentic NetOps: NetBrain Sets the Standard for Deploying AI in Network Operations29.5.2026 15:00:00 CEST | Press release
Newest expansion of the NetBrain platform delivers Agent Skills, AI Path Doctor, MCP Server, and expanded cross-domain integrations, extending the agentic capabilities already running in production at hundreds of enterprises. NetBrain Technologies, Inc. today announced major new platform features that advance Agentic NetOps from an emerging category to operational reality. NetBrain's clients are already deploying agents that are diagnosing and remediating issues across complex multi-vendor enterprise networks. These new features further extend the platform with new agent tooling, cross-domain context, and open interfaces for the broader agentic enterprise. Early customer outcomes show the magnitude of the shift: A leading health insurer used NetBrain's Deep Diagnosis agent to diagnose and resolve a weeks old VPN connectivity issue in under five minutes. A large manufacturer resolved a critical device issue with a single prompt, isolating the root cause across the network path in under
Adtran resolves long-running patent litigation, reinforcing commitment to defend innovation29.5.2026 14:00:00 CEST | Press release
News summary: Non-practicing entity litigation continues to create costly, time-consuming pressure across the technology industry Adtran has reached a full settlement following counterclaims, with payment made to Adtran and all claims dismissed with prejudice Outcome reflects Adtran’s commitment to defend its innovations, customers and business against meritless patent assertions Adtran today announced it has resolved a patent litigation matter, resulting in a full settlement and dismissal of all claims with prejudice. The case, initiated in 2020 by a non-practicing entity asserting five patents, was transferred to the US District Court for the Northern District of Alabama in 2021 following a successful motion by Adtran. Adtran subsequently filed counterclaims, including bad-faith patent assertion under Alabama statutory law. The settlement includes payment to Adtran to resolve its counterclaims. Terms of the agreement remain confidential. “This outcome reflects a disciplined and consi
Meiji Seika Pharma Invests in GHIC’s Global Health Security Fund29.5.2026 13:00:00 CEST | Press release
Meiji Seika Pharma Co., Ltd. (Headquarters: Tokyo, Japan; President and Representative Director: Toshiaki Nagasato) today announced that it has committed to invest in the Global Health Security Fund (GHSF), which is sponsored by Global Health Investment Corporation (GHIC), a New York-based nonprofit organization. Through this investment, Meiji Seika Pharma will support the acceleration of innovations addressing critical global health challenges, including pandemic preparedness and antimicrobial resistance (AMR). GHIC is a mission‑driven nonprofit organization that deploys private investment strategies to generate both global health impact and financial returns. GHIC recently closed its second fund in GHSF. With more than a decade of experience investing in the field of infectious disease, GHIC has contributed to addressing major global health challenges. Its portfolio companies have successfully commercialized more than a dozen products, collectively reaching over 600 million people wo
IFF Enters Into Agreement to Sell Its Food Ingredients Business to CVC29.5.2026 12:50:00 CEST | Press release
Transaction advances portfolio transformation, sharpens focus on higher-growth, higher-margin businesses, strengthens balance sheet, and enhances value creation for shareholders IFF (NYSE: IFF), a global leader in flavors, fragrances, food ingredients, and health and biosciences, today announced that it has entered into an agreement to sell its Food Ingredients business to funds advised by CVC Capital Partners, a leading global private markets manager, in a transaction that values the business at approximately $4.3 billion, representing an enterprise value-to-EBITDA multiple of approximately 10x. As part of the transaction, IFF has chosen to retain an approximately 10% minority equity interest in the business, or approximately $200 million, permitting continued collaboration and cooperation between IFF and Food Ingredients and allowing IFF and its shareholders to participate in future value creation under its new ownership. The transaction marks a significant step in IFF’s portfolio tr
BeOne Medicines Establishes Standard for Long-Term Disease Control in CLL with BRUKINSA 78-Month Data at ASCO 202629.5.2026 12:00:00 CEST | Press release
Data represents the longest reported follow-up for a next-generation BTK inhibitor in CLL, showing sustained disease control and benefit that extends beyond first-line therapyBRUKINSA plus next-generation BCL2 inhibitor sonrotoclax (ZS) delivered deep, durable, and rapid uMRD responses, raising the bar for potential time-limited treatments in CLLData reinforce BeOne’s leadership in CLL and the strength of its foundational hematology franchise BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, is advancing the treatment paradigm in chronic lymphocytic leukemia (CLL) at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting. With extensive long-term follow-up, the SEQUOIA study of BRUKINSA® (zanubrutinib) reinforces its role as the foundational BTK inhibitor, showing sustained disease control over years of therapy. These findings are further supported by real-world evidence across three large analyses encompassing more than 250,000 pati
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom